

Charles J. Ferro

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7457387/publications.pdf>

Version: 2024-02-01

216
papers

6,831
citations

57758

44
h-index

79698

73
g-index

230
all docs

230
docs citations

230
times ranked

8757
citing authors

#	ARTICLE	IF	CITATIONS
1	The Role of Uric Acid in the Acute Myocardial Infarction: A Narrative Review. <i>Angiology</i> , 2022, 73, 9-17.	1.8	11
2	Correlations, agreement and utility of frailty instruments in prevalent haemodialysis patients: baseline cohort data from the FITNESS study. <i>CKJ: Clinical Kidney Journal</i> , 2022, 15, 145-152.	2.9	15
3	End-stage kidney disease patients from ethnic minorities and mortality in coronavirus disease 2019. <i>Hemodialysis International</i> , 2022, 26, 83-93.	0.9	2
4	Sex differences in ambulatory blood pressure levels, control, and phenotypes of hypertension in kidney transplant recipients. <i>Journal of Hypertension</i> , 2022, 40, 356-363.	0.5	7
5	Assessment of hypertension in kidney transplantation by ambulatory blood pressure monitoring: a systematic review and meta-analysis. <i>CKJ: Clinical Kidney Journal</i> , 2022, 15, 31-42.	2.9	14
6	The burden of subclinical cardiovascular disease in children and young adults with chronic kidney disease and on dialysis. <i>CKJ: Clinical Kidney Journal</i> , 2022, 15, 287-294.	2.9	4
7	Reply. <i>Journal of Hypertension</i> , 2022, 40, 624-626.	0.5	0
8	Blood pressure targets in CKD 2021: the never-ending guidelines debacle. <i>CKJ: Clinical Kidney Journal</i> , 2022, 15, 845-851.	2.9	12
9	Renin-angiotensin system blockers during the COVID-19 pandemic: an update for patients with hypertension and chronic kidney disease. <i>CKJ: Clinical Kidney Journal</i> , 2022, 15, 397-406.	2.9	10
10	Risk for subsequent hypertension and cardiovascular disease after living kidney donation: is it clinically relevant?. <i>CKJ: Clinical Kidney Journal</i> , 2022, 15, 644-656.	2.9	3
11	Is Our Increasing Understanding of PCSK9 and Lp(a) Metabolism the Key to Unlocking the Paradox of Statins Ineffectiveness in Reducing Cardiovascular Events in Advanced CKD?. <i>SN Comprehensive Clinical Medicine</i> , 2022, 4, .	0.6	1
12	Sudden cardiac death in chronic renal disease: aetiology and risk reduction strategies. <i>Nephrology Dialysis Transplantation</i> , 2021, 36, 1386-1388.	0.7	7
13	Volume overload in hemodialysis: diagnosis, cardiovascular consequences, and management. <i>Nephrology Dialysis Transplantation</i> , 2021, 36, 2182-2193.	0.7	45
14	Routine serum biomarkers, but not dual-energy X-ray absorptiometry, correlate with cortical bone mineral density in children and young adults with chronic kidney disease. <i>Nephrology Dialysis Transplantation</i> , 2021, 36, 1872-1881.	0.7	15
15	Imbalanced turnover of collagen type III is associated with disease progression and mortality in high-risk chronic kidney disease patients. <i>CKJ: Clinical Kidney Journal</i> , 2021, 14, 593-601.	2.9	18
16	Intravenous iron therapy and the cardiovascular system: risks and benefits. <i>CKJ: Clinical Kidney Journal</i> , 2021, 14, 1067-1076.	2.9	12
17	The effect of admission and pre-admission serum creatinine as baseline to assess incidence and outcomes of acute kidney injury in acute medical admissions. <i>Nephrology Dialysis Transplantation</i> , 2021, , .	0.7	4
18	Sodium-glucose co-transporter-2 inhibitors for patients with diabetic and nondiabetic chronic kidney disease: a new era has already begun. <i>Journal of Hypertension</i> , 2021, 39, 1090-1097.	0.5	22

#	ARTICLE	IF	CITATIONS
19	Quantification of fibroblast growth factor 23 and N-terminal pro-B-type natriuretic peptide to identify patients with atrial fibrillation using a high-throughput platform: A validation study. <i>PLoS Medicine</i> , 2021, 18, e1003405.	8.4	11
20	Changes in left ventricular structure and function associated with renal transplantation: a systematic review and meta-analysis. <i>ESC Heart Failure</i> , 2021, 8, 2045-2057.	3.1	11
21	Renin-angiotensin system blockade in patients with chronic kidney disease: benefits, problems in everyday clinical use, and open questions for advanced renal dysfunction. <i>Journal of Human Hypertension</i> , 2021, 35, 499-509.	2.2	14
22	Early renal function trajectories, cytomegalovirus serostatus and long-term graft outcomes in kidney transplant recipients. <i>BMC Nephrology</i> , 2021, 22, 102.	1.8	4
23	Blood pressure monitoring in kidney transplantation: a systematic review on hypertension and target organ damage. <i>Nephrology Dialysis Transplantation</i> , 2021, 36, 1326-1346.	0.7	18
24	Acute kidney injury is more common in men than women after accounting for socioeconomic status, ethnicity, alcohol intake and smoking history. <i>Biology of Sex Differences</i> , 2021, 12, 30.	4.1	24
25	Coronary microvascular dysfunction is associated with degree of anaemia in end-stage renal disease. <i>BMC Cardiovascular Disorders</i> , 2021, 21, 211.	1.7	3
26	Cardiovascular Effects of Unilateral Nephrectomy in Living Kidney Donors at 5 Years. <i>Hypertension</i> , 2021, 77, 1273-1284.	2.7	8
27	Accuracy of Peridialytic, Intradialytic, and Scheduled Interdialytic Recordings in Detecting Elevated Ambulatory Blood Pressure in Hemodialysis Patients. <i>American Journal of Kidney Diseases</i> , 2021, 78, 630-639.e1.	1.9	7
28	Hypertension in kidney transplantation: a consensus statement of the "hypertension and the kidney"™ working group of the European Society of Hypertension. <i>Journal of Hypertension</i> , 2021, 39, 1513-1521.	0.5	16
29	MO108 ACCURACY OF PERIDIALYTIC, INTRADIALYTIC AND SCHEDULED INTERDIALYTIC RECORDINGS FOR DIAGNOSING HIGH AMBULATORY BLOOD PRESSURE IN HEMODIALYSIS. <i>Nephrology Dialysis Transplantation</i> , 2021, 36, .	0.7	0
30	Role of hypertension in kidney transplant recipients. <i>Journal of Human Hypertension</i> , 2021, 35, 958-969.	2.2	10
31	159...Myocardial fibrosis is associated with reduced coronary flow velocity reserve in end-stage renal disease. , 2021, , .		0
32	Screening for occult coronary artery disease in potential kidney transplant recipients: time for reappraisal?. <i>CKJ: Clinical Kidney Journal</i> , 2021, 14, 2472-2482.	2.9	3
33	Hyperkalemia in Chronic Kidney Disease in the New Era of Kidney Protection Therapies. <i>Drugs</i> , 2021, 81, 1467-1489.	10.9	22
34	Ambulatory blood pressure changes with lung ultrasound-guided dry-weight reduction in hypertensive hemodialysis patients: 12-month results of a randomized controlled trial. <i>Journal of Hypertension</i> , 2021, 39, 1444-1452.	0.5	4
35	Effects of Spironolactone and Chlorthalidone on Cardiovascular Structure and Function in Chronic Kidney Disease. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2021, 16, CJN.01930221.	4.5	6
36	Polypharmacology of clinical sodium glucose co-transport protein 2 inhibitors and relationship to suspected adverse drug reactions. <i>Pharmacology Research and Perspectives</i> , 2021, 9, e00867.	2.4	5

#	ARTICLE	IF	CITATIONS
37	Oxidative stress links periodontal inflammation and renal function. <i>Journal of Clinical Periodontology</i> , 2021, 48, 357-367.	4.9	34
38	Assessing bone mineralisation in children with chronic kidney disease: what clinical and research tools are available?. <i>Pediatric Nephrology</i> , 2020, 35, 937-957.	1.7	27
39	Cytomegalovirus seropositivity is independently associated with cardiovascular disease in non-dialysis dependent chronic kidney disease. <i>QJM - Monthly Journal of the Association of Physicians</i> , 2020, 113, 253-257.	0.5	4
40	Acute kidney injury calculated using admission serum creatinine underestimates 30-day and 1-year mortality after acute stroke. <i>CKJ: Clinical Kidney Journal</i> , 2020, 13, 46-54.	2.9	6
41	P1623 MAJOR ADVERSE CARDIOVASCULAR EVENTS (MACE) AFTER KIDNEY TRANSPLANTATION: A POPULATION-COHORT ANALYSIS OF ENGLISH TRANSPLANT CENTRES. <i>Nephrology Dialysis Transplantation</i> , 2020, 35, .	0.7	0
42	Relevance of physicochemical properties and functional pharmacology data to predict the clinical safety profile of direct oral anticoagulants. <i>Pharmacology Research and Perspectives</i> , 2020, 8, e00603.	2.4	14
43	Defining Myocardial Abnormalities Across the Stages of Chronic Kidney Disease. <i>JACC: Cardiovascular Imaging</i> , 2020, 13, 2357-2367.	5.3	27
44	P0254 MYOCARDIAL TISSUE CHARACTERIZATION IN LIVING KIDNEY DONORS 5 YEARS AFTER NEPHRECTOMY. <i>Nephrology Dialysis Transplantation</i> , 2020, 35, .	0.7	0
45	Changes in Blood Pressure and Arterial Hemodynamics following Living Kidney Donation. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2020, 15, 1330-1339.	4.5	9
46	Treatment-resistant hypertension in the hemodialysis population: a 44-h ambulatory blood pressure monitoring-based study. <i>Journal of Hypertension</i> , 2020, 38, 1849-1856.	0.5	15
47	Coronary flow velocity reserve and inflammatory markers in living kidney donors. <i>International Journal of Cardiology</i> , 2020, 320, 141-147.	1.7	6
48	Lipoprotein(a) Reduction in Persons with Cardiovascular Disease. <i>New England Journal of Medicine</i> , 2020, 382, e65.	27.0	8
49	Clinical Potential of Targeting Fibroblast Growth Factor β and β -Klotho in the Treatment of Uremic Cardiomyopathy. <i>Journal of the American Heart Association</i> , 2020, 9, e016041.	3.7	20
50	SGLT-2 Inhibitors to Treat Hyponatremia Associated with SIADH: A Novel Indication?. <i>American Journal of Nephrology</i> , 2020, 51, 553-555.	3.1	12
51	Association between non-malignant monoclonal gammopathy and adverse outcomes in chronic kidney disease: A cohort study. <i>PLoS Medicine</i> , 2020, 17, e1003050.	8.4	4
52	Management of atrial fibrillation in patients with chronic kidney disease in clinical practice: a joint European Heart Rhythm Association (EHRA) and European Renal Association/European Dialysis and Transplantation Association (ERA/EDTA) physician-based survey. <i>Europace</i> , 2020, 22, 496-505.	1.7	29
53	Anticoagulant strategies for the patient with chronic kidney disease. <i>Clinical Medicine</i> , 2020, 20, 151-155.	1.9	6
54	Serum Copeptin, NLPR3, and suPAR Levels among Patients with Autosomal-Dominant Polycystic Kidney Disease with and without Impaired Renal Function. <i>CardioRenal Medicine</i> , 2020, 10, 440-451.	1.9	4

#	ARTICLE	IF	CITATIONS
55	Hypertension Management in Patients With Autosomal Dominant Polycystic Kidney Disease: Time for a Paradigm Shift?. American Journal of Kidney Diseases, 2020, 76, 743.	1.9	1
56	Title is missing!. , 2020, 17, e1003050.		0
57	Title is missing!. , 2020, 17, e1003050.		0
58	Title is missing!. , 2020, 17, e1003050.		0
59	Title is missing!. , 2020, 17, e1003050.		0
60	Title is missing!. , 2020, 17, e1003050.		0
61	Subclinical Reactivation of Cytomegalovirus Drives CD4+CD28null T-Cell Expansion and Impaired Immune Response to Pneumococcal Vaccination in Antineutrophil Cytoplasmic Antibody-Associated Vasculitis. Journal of Infectious Diseases, 2019, 219, 234-244.	4.0	26
62	FO082PROGRESSION OF MYOCARDIAL FIBROSIS IN CHRONIC KIDNEY DISEASE. Nephrology Dialysis Transplantation, 2019, 34, .	0.7	2
63	Is blood pressure measured correctly in dialysis centres? Physicians' and patients' views. Nephrology Dialysis Transplantation, 2019, 34, 1612-1615.	0.7	6
64	Coronary microvascular dysfunction: a key step in the development of uraemic cardiomyopathy?. Heart, 2019, 105, 1302-1309.	2.9	24
65	Chronic kidney disease and valvular heart disease: conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference. Kidney International, 2019, 96, 836-849.	5.2	80
66	Chronic Kidney Disease and Coronary Artery Disease. Journal of the American College of Cardiology, 2019, 74, 1823-1838.	2.8	403
67	Early effects of kidney transplantation on the heart - A cardiac magnetic resonance multi-parametric study. International Journal of Cardiology, 2019, 293, 272-277.	1.7	21
68	Renal function and the long-term clinical outcomes of cardiac resynchronization therapy with or without defibrillation. PACE - Pacing and Clinical Electrophysiology, 2019, 42, 595-602.	1.2	5
69	SGLT-2 inhibitors and GLP-1 receptor agonists for nephroprotection and cardioprotection in patients with diabetes mellitus and chronic kidney disease. A consensus statement by the EURECA-m and the DIABESITY working groups of the ERA-EDTA. Nephrology Dialysis Transplantation, 2019, 34, 208-230.	0.7	147
70	Arterial stiffness in chronic kidney disease. Current Opinion in Nephrology and Hypertension, 2019, 28, 527-536.	2.0	11
71	Myocardial characterization in pre-dialysis chronic kidney disease: a study of prevalence, patterns and outcomes. BMC Cardiovascular Disorders, 2019, 19, 295.	1.7	7
72	Vive les Differences! A case for optimism in the treatment of patients with heart failure and preserved ejection fraction?. International Journal of Clinical Practice, 2019, 73, e13307.	1.7	0

#	ARTICLE	IF	CITATIONS
73	Glucocorticoid activation by 11 β -hydroxysteroid dehydrogenase enzymes in relation to inflammation and glycaemic control in chronic kidney disease: A cross-sectional study. <i>Clinical Endocrinology</i> , 2019, 90, 241-249.	2.4	25
74	Cardiovascular, thromboembolic and renal outcomes in IgA vasculitis (Henoch-Schönlein purpura): a retrospective cohort study using routinely collected primary care data. <i>Annals of the Rheumatic Diseases</i> , 2019, 78, 261-269.	0.9	50
75	Arterial stiffness alone does not explain arteriovenous fistula outcomes. <i>Journal of Vascular Access</i> , 2018, 19, 63-68.	0.9	8
76	Diffuse Myocardial Interstitial Fibrosis and Dysfunction in Early Chronic Kidney Disease. <i>American Journal of Cardiology</i> , 2018, 121, 656-660.	1.6	26
77	Premature coronary artery disease and early stage chronic kidney disease. <i>QJM - Monthly Journal of the Association of Physicians</i> , 2018, 111, 683-686.	0.5	4
78	Results of Serial Myocardial Perfusion Imaging in End-Stage Renal Disease. <i>American Journal of Cardiology</i> , 2018, 121, 661-667.	1.6	4
79	Use of oral anticoagulants in patients with atrial fibrillation and renal dysfunction. <i>Nature Reviews Nephrology</i> , 2018, 14, 337-351.	9.6	89
80	Myocardial tissue characterisation in progressive CKD: is diffuse interstitial fibrosis the key intermediary of uraemic cardiomyopathy?. , 2018, , .		0
81	A novel biomarker of laminin turnover is associated with disease progression and mortality in chronic kidney disease. <i>PLoS ONE</i> , 2018, 13, e0204239.	2.5	15
82	Lipid management in patients with chronic kidney disease. <i>Nature Reviews Nephrology</i> , 2018, 14, 727-749.	9.6	153
83	Incidence and impact on outcomes of acute kidney injury after a stroke: a systematic review and meta-analysis. <i>BMC Nephrology</i> , 2018, 19, 283.	1.8	36
84	Which anticoagulants should be used for stroke prevention in non-valvular atrial fibrillation and severe chronic kidney disease?. <i>Current Opinion in Nephrology and Hypertension</i> , 2018, 27, 420-425.	2.0	9
85	Frailty Intervention Trial in End-Stage patients on haemodialysis (FITNESS): study protocol for a randomised controlled trial. <i>Trials</i> , 2018, 19, 457.	1.6	16
86	The host cellular immune response to cytomegalovirus targets the endothelium and is associated with increased arterial stiffness in ANCA-associated vasculitis. <i>Arthritis Research and Therapy</i> , 2018, 20, 194.	3.5	20
87	Humoral immunity to memory antigens and pathogens is maintained in patients with chronic kidney disease. <i>PLoS ONE</i> , 2018, 13, e0195730.	2.5	4
88	Chronic kidney disease as a cardiovascular risk factor: lessons from kidney donors. <i>Journal of the American Society of Hypertension</i> , 2018, 12, 497-505.e4.	2.3	13
89	Association between urinary free light chains and progression to end stage renal disease in chronic kidney disease. <i>PLoS ONE</i> , 2018, 13, e0197043.	2.5	6
90	Patterns of late gadolinium enhancement in chronic kidney disease: a predictor of clinical outcome data?. , 2018, , .		0

#	ARTICLE	IF	CITATIONS
91	Fractures in Kidney Transplant Recipients: A Comparative Study Between England and New York State. <i>Experimental and Clinical Transplantation</i> , 2018, 16, 410-418.	0.5	3
92	The Nephroprotective Effect of Folic Acid—Only a Matter of Homocysteine?. <i>JAMA Internal Medicine</i> , 2017, 177, 286.	5.1	0
93	Hypertension in dialysis patients: a consensus document by the European Renal and Cardiovascular Medicine (EURECA-m) working group of the European Renal Association—European Dialysis and Transplant Association (ERA-EDTA) and the Hypertension and the Kidney working group of the European Society of Hypertension (ESH)*. <i>Nephrology Dialysis Transplantation</i> , 2017, 32, 620-640.	0.7	133
94	Hypertension in dialysis patients. <i>Journal of Hypertension</i> , 2017, 35, 657-676.	0.5	56
95	Outcomes After Weekend Admission for Deceased Donor Kidney Transplantation. <i>Transplantation</i> , 2017, 101, 2244-2252.	1.0	21
96	A randomized, multicenter, open-label, blinded end point trial comparing the effects of spironolactone to chlorthalidone on left ventricular mass in patients with early-stage chronic kidney disease: Rationale and design of the SPIRO-CKD trial. <i>American Heart Journal</i> , 2017, 191, 37-46.	2.7	10
97	Dialysis Following Transcatheter Aortic Valve Replacement: Risk Factors and Outcomes. <i>JACC: Cardiovascular Interventions</i> , 2017, 10, 2040-2047.	2.9	31
98	Urinary endotrophin predicts disease progression in patients with chronic kidney disease. <i>Scientific Reports</i> , 2017, 7, 17328.	3.3	52
99	Definitions of Resistant Hypertension and Epidemiology of Resistant Hypertension. , 2017, , 1-12.		0
100	10—Cardiac alterations after renal transplant; controversies unravelled by cardiac mri. <i>Heart</i> , 2017, 103, A6-A7.	2.9	1
101	11—Cpex testing detects subclinical cardiac limitation to exercise in early stage ckd. <i>Heart</i> , 2017, 103, A7.1-A7.	2.9	1
102	INfluence of Successful Periodontal Intervention in REnal Disease (INSPIRED): study protocol for a randomised controlled pilot clinical trial. <i>Trials</i> , 2017, 18, 535.	1.6	7
103	Hospital acquired Acute Kidney Injury is associated with increased mortality but not increased readmission rates in a UK acute hospital. <i>BMC Nephrology</i> , 2017, 18, 317.	1.8	21
104	MP387CARDIAC LIMITATION OCCURS EARLY IN CKD, AND CANNOT BE FULLY EXPLAINED BY ISCHAEMIA OR REDUCED LV COMPLIANCE AS MEASURED BY DIASTOLIC FUNCTION DURING EXERCISE. <i>Nephrology Dialysis Transplantation</i> , 2017, 32, iii570-iii570.	0.7	0
105	MP392CARDIOPULMONARY EXERCISE TESTING DETECTS SUBCLINICAL CARDIAC LIMITATION TO EXERCISE IN EARLY STAGE CKD. <i>Nephrology Dialysis Transplantation</i> , 2017, 32, iii572-iii572.	0.7	0
106	CKD Associated Cardiomyopathy: Molecular Mechanisms, Imaging Modalities, Disease Evolution and Interventions. , 2017, , 45-58.		1
107	Serum endotrophin, a type VI collagen cleavage product, is associated with increased mortality in chronic kidney disease. <i>PLoS ONE</i> , 2017, 12, e0175200.	2.5	56
108	SPRINTing towards trials of blood pressure reduction to reduce CKD progression?. <i>European Heart Journal Quality of Care & Clinical Outcomes</i> , 2016, 2, 229-230.	4.0	1

#	ARTICLE	IF	CITATIONS
109	Valaciclovir to prevent Cytomegalovirus mediated adverse modulation of the immune system in ANCA-associated vasculitis (CANVAS): study protocol for a randomised controlled trial. <i>Trials</i> , 2016, 17, 338.	1.6	12
110	Health-Related Quality of Life Impacts Mortality but Not Progression to End-Stage Renal Disease in Pre-Dialysis Chronic Kidney Disease: A Prospective Observational Study. <i>PLoS ONE</i> , 2016, 11, e0165675.	2.5	41
111	MP728SOCIOECONOMIC DEPRIVATION AND OUTCOMES AFTER KIDNEY TRANSPLANTATION. <i>Nephrology Dialysis Transplantation</i> , 2016, 31, i581-i581.	0.7	0
112	Risk of post-transplantation diabetes mellitus is greater in South Asian versus Caucasian kidney allograft recipients. <i>Transplant International</i> , 2016, 29, 727-739.	1.6	15
113	Association between periodontitis and mortality in stages 3-5 chronic kidney disease: <scp>NHANES III</scp> and linked mortality study. <i>Journal of Clinical Periodontology</i> , 2016, 43, 104-113.	4.9	110
114	Results and lessons from the Spironolactone To Prevent Cardiovascular Events in Early Stage Chronic Kidney Disease (STOP-CKD) randomised controlled trial. <i>BMJ Open</i> , 2016, 6, e010519.	1.9	16
115	Cytomegalovirus infection is associated with an increase in systolic blood pressure in older individuals. <i>QJM - Monthly Journal of the Association of Physicians</i> , 2016, 109, 595-600.	0.5	32
116	Associations of Blood Pressure With Geographical Latitude, Solar Radiation, and Ambient Temperature: Results From the Chilean Health Survey, 2009-2010: Table A1.. <i>American Journal of Epidemiology</i> , 2016, 183, 1071-1073.	3.4	29
117	Re: assessment of myocardial fibrosis with T1 mapping MRI. <i>Clinical Radiology</i> , 2016, 71, 1309-1310.	1.1	0
118	Effect of mineralocorticoid receptor antagonists on proteinuria and progression of chronic kidney disease: a systematic review and meta-analysis. <i>BMC Nephrology</i> , 2016, 17, 127.	1.8	134
119	Caveolin-1 single-nucleotide polymorphism and arterial stiffness in non-dialysis chronic kidney disease. <i>Nephrology Dialysis Transplantation</i> , 2016, 31, 1140-1144.	0.7	10
120	Serum tryptase concentration and progression to end-stage renal disease. <i>European Journal of Clinical Investigation</i> , 2016, 46, 460-474.	3.4	20
121	Cardiovascular Effects of Unilateral Nephrectomy in Living Kidney Donors. <i>Hypertension</i> , 2016, 67, 368-377.	2.7	85
122	Prognostic Utility of Calcium Scoring as an Adjunct to Stress Myocardial Perfusion Scintigraphy in End-Stage Renal Disease. <i>American Journal of Cardiology</i> , 2016, 117, 1387-1396.	1.6	17
123	Modulation of stroke risk in chronic kidney disease. <i>CKJ: Clinical Kidney Journal</i> , 2016, 9, 29-38.	2.9	23
124	Letter by Edwards et al Regarding Article, "Coronary Microvascular Rarefaction and Myocardial Fibrosis in Heart Failure With Preserved Ejection Fraction". <i>Circulation</i> , 2015, 132, e204.	1.6	0
125	37...Cardiovascular Effects of Unilateral Nephrectomy in Human Kidney Donors. <i>Heart</i> , 2015, 101, A20.2-A21.	2.9	0
126	Fracture risk and mortality post-kidney transplantation. <i>Clinical Transplantation</i> , 2015, 29, 1004-1012.	1.6	30

#	ARTICLE	IF	CITATIONS
127	SPO28CAVEOLIN-1 POLYMORPHISM ASSOCIATION WITH ARTERIAL STIFFNESS IN NON-DIALYSIS CKD. <i>Nephrology Dialysis Transplantation</i> , 2015, 30, iii389-iii390.	0.7	0
128	Cardiovascular actions of mineralocorticoid receptor antagonists in patients with chronic kidney disease: A systematic review and meta-analysis of randomized trials. <i>JRAAS - Journal of the Renin-Angiotensin-Aldosterone System</i> , 2015, 16, 599-613.	1.7	17
129	Comparison of magnetic resonance feature tracking for systolic and diastolic strain and strain rate calculation with spatial modulation of magnetization imaging analysis. <i>Journal of Magnetic Resonance Imaging</i> , 2015, 41, 1000-1012.	3.4	87
130	Acute Care QUALiTY in chronic Kidney disease (ACQUATIK): a prospective cohort study exploring outcomes of patients with chronic kidney disease. <i>BMJ Open</i> , 2015, 5, e006987-e006987.	1.9	3
131	Impact of renal function on survival after transcatheter aortic valve implantation (TAVI): an analysis of the UK TAVI registry. <i>Heart</i> , 2015, 101, 546-552.	2.9	84
132	Chronic kidney disease in patients with cardiac rhythm disturbances or implantable electrical devices: clinical significance and implications for decision making-a position paper of the European Heart Rhythm Association endorsed by the Heart Rhythm Society and the Asia Pacific Heart Rhythm Society. <i>Europace</i> , 2015, 17, 1169-1196.	1.7	138
133	Coronary Artery Calcium Assessment in CKD: Utility in Cardiovascular Disease Risk Assessment and Treatment?. <i>American Journal of Kidney Diseases</i> , 2015, 65, 937-948.	1.9	37
134	Variability in cardiac MR measurement of left ventricular ejection fraction, volumes and mass in healthy adults: defining a significant change at 1 year. <i>British Journal of Radiology</i> , 2015, 88, 20140831.	2.2	29
135	Diffuse Interstitial Fibrosis and Myocardial Dysfunction in Early Chronic Kidney Disease. <i>American Journal of Cardiology</i> , 2015, 115, 1311-1317.	1.6	87
136	Bayesian Analysis of Glomerular Filtration Rate Trajectories in Kidney Transplant Recipients. <i>Transplantation</i> , 2015, 99, 533-539.	1.0	8
137	Phosphate: are we squandering a scarce commodity?. <i>Nephrology Dialysis Transplantation</i> , 2015, 30, 163-168.	0.7	7
138	Endothelial Nitric Oxide Synthase Single Nucleotide Polymorphism and Left Ventricular Function in Early Chronic Kidney Disease. <i>PLoS ONE</i> , 2015, 10, e0116160.	2.5	15
139	Cognitive and Kidney Function: Results from a British Birth Cohort Reaching Retirement Age. <i>PLoS ONE</i> , 2014, 9, e86743.	2.5	18
140	Central pulse pressure in patients with chronic kidney disease and in renal transplant recipients. <i>Journal of Human Hypertension</i> , 2014, 28, 180-185.	2.2	5
141	The relationship between high-sensitivity CRP and polyclonal Free Light Chains as markers of inflammation in chronic disease. <i>International Journal of Laboratory Hematology</i> , 2014, 36, 415-424.	1.3	26
142	Effect of A Reduction in glomerular filtration rate after NEphrectomy on arterial STiffness and central hemodynamics: Rationale and design of the EARNEST study. <i>American Heart Journal</i> , 2014, 167, 141-149.e2.	2.7	15
143	Serum Polyclonal Immunoglobulin Free Light Chain Levels Predict Mortality in People With Chronic Kidney Disease. <i>Mayo Clinic Proceedings</i> , 2014, 89, 615-622.	3.0	37
144	Spironolactone increases serum uric acid levels in patients with chronic kidney disease. <i>Journal of Human Hypertension</i> , 2014, 28, 210-211.	2.2	8

#	ARTICLE	IF	CITATIONS
145	Vitamin B12 deficiency is associated with geographical latitude and solar radiation in the older population. <i>Journal of Photochemistry and Photobiology B: Biology</i> , 2014, 140, 8-13.	3.8	14
146	Defining the Natural History of Uremic Cardiomyopathy in Chronic Kidney Disease. <i>JACC: Cardiovascular Imaging</i> , 2014, 7, 703-714.	5.3	92
147	The periodontal health component of the Renal Impairment In Secondary Care (RIISC) cohort study: a description of the rationale, methodology and initial baseline results. <i>Journal of Clinical Periodontology</i> , 2014, 41, 653-661.	4.9	24
148	Spironolactone to prevent cardiovascular events in early-stage chronic kidney disease (STOP-CKD): study protocol for a randomized controlled pilot trial. <i>Trials</i> , 2014, 15, 158.	1.6	9
149	Benefits of Aldosterone Receptor Antagonism in Chronic Kidney Disease (BARACK D) trial: a multi-centre, prospective, randomised, open, blinded end-point, 36-month study of 2,616 patients within primary care with stage 3b chronic kidney disease to compare the efficacy of spironolactone 25Åmg once daily in addition to routine care on mortality and cardiovascular outcomes versus routine care alone: study protocol for a randomized controlled trial. <i>Trials</i> , 2014, 15, 160.	1.6	29
150	Predicting 5-Year Risk of Kidney Transplant Failure: A Prediction Instrument Using Data Available at 1 Year Posttransplantation. <i>American Journal of Kidney Diseases</i> , 2014, 63, 643-651.	1.9	55
151	The EARNEST Study: Interarm blood pressure differences should also be recorded. <i>American Heart Journal</i> , 2014, 168, e9.	2.7	0
152	Allopurinol Is an Independent Determinant of Improved Arterial Stiffness in Chronic Kidney Disease: A Cross-Sectional Study. <i>PLoS ONE</i> , 2014, 9, e91961.	2.5	26
153	The natural history of, and risk factors for, progressive Chronic Kidney Disease (CKD): the Renal Impairment in Secondary care (RIISC) study; rationale and protocol. <i>BMC Nephrology</i> , 2013, 14, 95.	1.8	37
154	Impaired circumferential and longitudinal myocardial deformation in early stage chronic kidney disease: the earliest features of uremic cardiomyopathy. <i>Journal of Cardiovascular Magnetic Resonance</i> , 2013, 15, .	3.3	3
155	Optimising the accuracy of blood pressure monitoring in chronic kidney disease: the utility of BpTRU. <i>BMC Nephrology</i> , 2013, 14, 218.	1.8	20
156	Early-Life Overweight Trajectory and CKD in the 1946 British Birth Cohort Study. <i>American Journal of Kidney Diseases</i> , 2013, 62, 276-284.	1.9	44
157	Effects of age and chronic kidney disease on regional aortic distensibility: A cardiovascular magnetic resonance study. <i>International Journal of Cardiology</i> , 2013, 168, 4249-4254.	1.7	17
158	Atrial Fibrillation in CKD: Balancing the Risks and Benefits of Anticoagulation. <i>American Journal of Kidney Diseases</i> , 2013, 62, 615-632.	1.9	69
159	Cardiovascular Effects of Sevelamer in Stage 3 CKD. <i>Journal of the American Society of Nephrology: JASN</i> , 2013, 24, 842-852.	6.1	108
160	Association between Younger Age When First Overweight and Increased Risk for CKD. <i>Journal of the American Society of Nephrology: JASN</i> , 2013, 24, 813-821.	6.1	56
161	Arterial disease in chronic kidney disease. <i>Heart</i> , 2013, 99, 365-372.	2.9	119
162	Low birth weight, later renal function, and the roles of adulthood blood pressure, diabetes, and obesity in a British birth cohort. <i>Kidney International</i> , 2013, 84, 1262-1270.	5.2	53

#	ARTICLE	IF	CITATIONS
163	Skewing of Female X-Chromosome Inactivation. <i>Transplantation</i> , 2013, 95, e25-e28.	1.0	7
164	Cytomegalovirus Seropositivity Is Associated with Increased Arterial Stiffness in Patients with Chronic Kidney Disease. <i>PLoS ONE</i> , 2013, 8, e55686.	2.5	33
165	Serum phosphate is associated with left ventricular mass in patients with chronic kidney disease: a cardiac magnetic resonance study. <i>Heart</i> , 2012, 98, 219-224.	2.9	64
166	Unexpected benefits of participation in a clinical trial: abdominal aortic aneurysms in patients with chronic kidney disease. <i>QJM - Monthly Journal of the Association of Physicians</i> , 2012, 105, 1213-1216.	0.5	1
167	Understanding the effects of chronic kidney disease on cardiovascular risk: are there lessons to be learnt from healthy kidney donors?. <i>Journal of Human Hypertension</i> , 2012, 26, 141-148.	2.2	18
168	Randomised-controlled trials in chronic kidney disease - a call to arms!. <i>International Journal of Clinical Practice</i> , 2012, 66, 913-915.	1.7	7
169	Hypertension, arterial haemodynamics and left ventricular disease: historical observations. <i>QJM - Monthly Journal of the Association of Physicians</i> , 2012, 105, 709-716.	0.5	7
170	Endothelial dysfunction and cardiovascular disease in early-stage chronic kidney disease: Cause or association?. <i>Atherosclerosis</i> , 2012, 223, 86-94.	0.8	107
171	Aortic Calcification and Femoral Bone Density Are Independently Associated with Left Ventricular Mass in Patients with Chronic Kidney Disease. <i>PLoS ONE</i> , 2012, 7, e39241.	2.5	10
172	Invite all donors to participate in follow-up studies. <i>BMJ, The</i> , 2012, 344, e2724-e2724.	6.0	2
173	The safety and tolerability of spironolactone in patients with mild to moderate chronic kidney disease. <i>British Journal of Clinical Pharmacology</i> , 2012, 73, 447-454.	2.4	55
174	Serum Phosphate Measured at 6 and 12 Months After Successful Kidney Transplant Is Independently Associated With Subsequent Graft Loss. <i>Experimental and Clinical Transplantation</i> , 2012, 10, 119-124.	0.5	11
175	Serum phosphate but not pulse wave velocity predicts decline in renal function in patients with early chronic kidney disease. <i>Nephrology Dialysis Transplantation</i> , 2011, 26, 2576-2582.	0.7	64
176	Serum phosphate and calcium concentrations are associated with reduced patient survival following kidney transplantation. <i>Clinical Transplantation</i> , 2011, 25, 406-416.	1.6	27
177	Evaluating the effects of sevelamer carbonate on cardiovascular structure and function in chronic renal impairment in Birmingham: the CRIB-PHOS randomised controlled trial. <i>Trials</i> , 2011, 12, 30.	1.6	10
178	A systematic review of the use of opioid medication for those with moderate to severe cancer pain and renal impairment: A European Palliative Care Research Collaborative opioid guidelines project. <i>Palliative Medicine</i> , 2011, 25, 525-552.	3.1	153
179	Does immunosuppressant medication lower blood pressure and arterial stiffness in patients with chronic kidney disease? An observational study. <i>Hypertension Research</i> , 2011, 34, 113-119.	2.7	17
180	Prediction of ESRD and Death Among People With CKD: The Chronic Renal Impairment in Birmingham (CRIB) Prospective Cohort Study. <i>American Journal of Kidney Diseases</i> , 2010, 56, 1082-1094.	1.9	144

#	ARTICLE	IF	CITATIONS
181	Effect of Spironolactone on Left Ventricular Systolic and Diastolic Function in Patients With Early Stage Chronic Kidney Disease. <i>American Journal of Cardiology</i> , 2010, 106, 1505-1511.	1.6	55
182	An increased risk of ischemic heart disease in Wegener's granulomatosis: Comment on the article by Faurischou et al. <i>Arthritis and Rheumatism</i> , 2010, 62, 637-638.	6.7	1
183	The effect of spironolactone upon corticosteroid hormone metabolism in patients with early stage chronic kidney disease. <i>Clinical Endocrinology</i> , 2010, 73, 566-572.	2.4	19
184	Republished paper: Arterial stiffness in chronic kidney disease: causes and consequences. <i>Postgraduate Medical Journal</i> , 2010, 86, 560-566.	1.8	15
185	Reduction of blood pressure already in the normal range further regresses left ventricular mass. <i>Heart</i> , 2010, 96, 1080-1080.	2.9	2
186	Arterial stiffness in chronic kidney disease: causes and consequences. <i>Heart</i> , 2010, 96, 817-823.	2.9	124
187	THE IMPORTANCE OF RENIN-ANGIOTENSIN BLOCKADE IN PATIENTS WITH CARDIO-RENAL DISEASE. <i>Journal of Renal Care</i> , 2010, 36, 97-105.	1.2	3
188	Management of pain in renal failure. , 2010, , 139-188.		9
189	Is lowering phosphate exposure the key to preventing arterial stiffening with age?. <i>Heart</i> , 2009, 95, 1770-1772.	2.9	23
190	Increased incidence of cardiovascular events in patients with antineutrophil cytoplasmic antibody-associated vasculitides: A matched-pair cohort study. <i>Arthritis and Rheumatism</i> , 2009, 60, 3493-3500.	6.7	110
191	Effect of Spironolactone on Left Ventricular Mass and Aortic Stiffness in Early-Stage Chronic Kidney Disease. <i>Journal of the American College of Cardiology</i> , 2009, 54, 505-512.	2.8	256
192	Management of pain in chronic kidney disease. <i>Progress in Palliative Care</i> , 2009, 17, 186-195.	1.2	11
193	Subclinical Abnormalities of Left Ventricular Myocardial Deformation in Early-Stage Chronic Kidney Disease: The Precursor of Uremic Cardiomyopathy?. <i>Journal of the American Society of Echocardiography</i> , 2008, 21, 1293-1298.	2.8	84
194	Aortic distensibility and arterial-ventricular coupling in early chronic kidney disease: a pattern resembling heart failure with preserved ejection fraction. <i>Heart</i> , 2008, 94, 1038-1043.	2.9	79
195	Myocardial disease in systemic vasculitis and autoimmune disease detected by cardiovascular magnetic resonance. <i>Rheumatology</i> , 2007, 46, 1208-1209.	1.9	25
196	Haemodynamic and renal effects of endothelin receptor antagonism in patients with chronic kidney disease. <i>Nephrology Dialysis Transplantation</i> , 2007, 22, 3228-3234.	0.7	47
197	Cross-Sectional Analysis of Abnormalities of Mineral Homeostasis, Vitamin D and Parathyroid Hormone in a Cohort of Pre-Dialysis Patients. <i>Nephron Clinical Practice</i> , 2007, 107, c109-c116.	2.3	42
198	The treatment of coronary artery disease in patients with chronic kidney disease. <i>QJM - Monthly Journal of the Association of Physicians</i> , 2006, 99, 723-736.	0.5	34

#	ARTICLE	IF	CITATIONS
199	Reproducibility of derived central arterial waveforms in patients with chronic renal failure. <i>Clinical Science</i> , 2002, 103, 59-65.	4.3	60
200	Forearm vasoconstriction to endothelin-1 is impaired, but constriction to sarafotoxin 6c and vasodilatation to BQ-123 unaltered, in patients with essential hypertension. <i>Clinical Science</i> , 2002, 103, 53S-58S.	4.3	13
201	Reproducibility of derived central arterial waveforms in patients with chronic renal failure. <i>Clinical Science</i> , 2002, 103, 59.	4.3	34
202	The impact of arteriovenous fistula formation on central hemodynamic pressures in chronic renal failure patients: A prospective study. <i>American Journal of Kidney Diseases</i> , 2002, 40, 753-759.	1.9	82
203	Central aortic pressure augmentation in stable renal transplant recipients. <i>Kidney International</i> , 2002, 62, 166-171.	5.2	61
204	Big endothelin-3 constricts forearm resistance vessels but not hand veins in humans. <i>Clinical Pharmacology and Therapeutics</i> , 2000, 68, 67-74.	4.7	1
205	Endothelin receptor antagonism in patients with chronic heart failure. <i>Cardiovascular Research</i> , 2000, 47, 166-172.	3.8	38
206	Substance P-induced vasodilatation is mediated by the neurokinin type 1 receptor but does not contribute to basal vascular tone in man. <i>British Journal of Clinical Pharmacology</i> , 1999, 48, 336-344.	2.4	36
207	Impaired cholinergic dilator response of resistance arteries isolated from patients with Raynaud's disease. <i>British Journal of Clinical Pharmacology</i> , 1999, 47, 507-513.	2.4	22
208	Bosentan in Essential Hypertension. <i>New England Journal of Medicine</i> , 1998, 339, 346-347.	27.0	15
209	Inhibition of Neutral Endopeptidase Causes Vasoconstriction of Human Resistance Vessels In Vivo. <i>Circulation</i> , 1998, 97, 2323-2330.	1.6	158
210	Functional Studies in Small Arteries Do Not Support a Primary Role for Endothelin in the Pathogenesis of Raynaud's Disease. <i>Journal of Cardiovascular Pharmacology</i> , 1998, 31, S473-S476.	1.9	6
211	Endothelial Dysfunction and Hypertension. <i>Drugs</i> , 1997, 53, 30-41.	10.9	57
212	The increase in human plasma immunoreactive endothelin but not big endothelin or its C-terminal fragment induced by systemic administration of the endothelin antagonist TAK-044. <i>British Journal of Pharmacology</i> , 1996, 119, 311-314.	5.4	62
213	The Clinical Potential of Endothelin Receptor Antagonists in Cardiovascular Medicine. <i>Drugs</i> , 1996, 51, 12-27.	10.9	70
214	Systemic Endothelin Receptor Blockade Decreases Peripheral Vascular Resistance and Blood Pressure in Humans. <i>Circulation</i> , 1996, 93, 1860-1870.	1.6	257
215	Trimming the fat: is there a health economic case for the use of new lipid-lowering drugs in chronic kidney disease? A scoping review. <i>CKJ: Clinical Kidney Journal</i> , 0, , .	2.9	0
216	Renal artery stenting in the correct patients with atherosclerotic renovascular disease: time for a proper renal and cardiovascular outcome study?. <i>CKJ: Clinical Kidney Journal</i> , 0, , .	2.9	2